Dr. Sgroi is working to find better ways to identify patients who are at risk for developing breast cancer and to identify those who are likely to benefit from targeted drug therapies.
Dr. Sgroi is the subspecialty co-head of Breast Pathology at the Massachusetts General Hospital. Dr Sgroi received his undergraduate degree from Bowdoin College and his medical degree from the University of Connecticut School of Medicine. After completing a residency in anatomic pathology at Massachusetts General Hospital, Dr. Sgroi completed a postdoctoral research fellowship in molecular pathology under the direction of Dr. Ivan Stamenkovic at Massachusetts General Hospital. He is a member and principal investigator in the Molecular Pathology Research Unit and Center for Cancer Research. The Sgroi Lab investigates the molecular genetic basis of human breast cancer and has utilized gene expression and proteomic technologies to better understand breast cancer progression.
Human Breast Cancer Anti-Hormonal Resistance: Dr. Sgroi has shown that gene expression alterations are powerful predictors of breast cancer outcome and therapeutic response. His laboratory has focused on determining the clinical utility of the HOXB13:IL17BR and MGI biomarkers in estrogen receptor-positive, lymph node negative breast cancer patients, and understanding the molecular functional role of HOXB13 and IL17BR as it relates to anti-hormonal therapeutic response. Dr. Sgroi is also affiliated with the Dana-Farber/Harvard Cancer Center?s Breast Cancer and Cancer Genetics programs. Find more information on the Sgroi Lab website, or read about Dr. Sgroi's research in the 2014 annual report of the Center for Cancer Research. For more information about research concepts, co-authors, and to see a timeline, visit Dr. Sgroi's profile page at the Harvard Clinical and Translational Science Center.
A comparison of three methods of predicting recurrence risk in women treated for estrogen-receptor-positive breast cancer finds that only the breast cancer index – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of estrogen-blocking treatment.